GlyProVac ApS aims to design and develop novel, efficient bacterial vaccine candidates based on a proprietary platform technology BEMAP. Using BEMAP, they have revealed that both benign as well as disease causing bacteria such as E. coli, Pseudomonas aeruginosa and Shigella, extensively modify their proteins with distinct sugar molecules, known as O-linked glycosylations. These modifications drastically influence the topology of the protein and are particularly well recognized by the human immune response, and inclusion of these modifications are crucial for the development of efficient bacterial vaccines. GlyProVac was founded in 2018.